Radcliffe Capital Management L.P. Purchases 151,403 Shares of Oaktree Acquisition Corp. III Life Sciences $OACC

Radcliffe Capital Management L.P. boosted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 67.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,065 shares of the company’s stock after buying an additional 151,403 shares during the period. Radcliffe Capital Management L.P. owned about 1.68% of Oaktree Acquisition Corp. III Life Sciences worth $3,989,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of OACC. Lighthouse Investment Partners LLC raised its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 88.9% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock valued at $8,882,000 after buying an additional 400,000 shares in the last quarter. Sculptor Capital LP boosted its position in shares of Oaktree Acquisition Corp. III Life Sciences by 6.1% during the 4th quarter. Sculptor Capital LP now owns 530,537 shares of the company’s stock valued at $5,613,000 after acquiring an additional 30,537 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Oaktree Acquisition Corp. III Life Sciences in the first quarter valued at about $5,417,000. Moore Capital Management LP bought a new stake in Oaktree Acquisition Corp. III Life Sciences in the second quarter valued at about $5,502,000. Finally, Millennium Management LLC acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the first quarter worth about $4,848,000.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.9%

Shares of NASDAQ:OACC opened at $10.76 on Wednesday. The business’s fifty day moving average price is $10.67 and its two-hundred day moving average price is $10.64. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $10.30 and a fifty-two week high of $10.74.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last issued its quarterly earnings data on Thursday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.